Evidence map›Paper›PMID 32162166›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2020

Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.

Xiaoli Liao, Nianyue Wu, Dongfeng Liu, Bowei Shuai, Shilei Li, Ke Li

Registry-linked trialAbstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06928519 (Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06928519 recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study

TypeobservationalSponsorYousheng XiaoRan2025 to 2027Enrolled216ConditionsParkinson Disease (PD)
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Combination Pharmacology for ALS: A Mechanistic Rationale.International journal of molecular sciences · 2026
    Review
  4. Global, regional, and national burden of Early-onset Parkinson's disease: A comprehensive analysis and forecast, 1990-2021.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Entacapone promotes hippocampal neurogenesis in mice.Neural regeneration research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiaoli LiaoSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Nianyue WuSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Dongfeng LiuSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Bowei ShuaiSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Shilei LiSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China.
Ke LiSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China. colinlike@163.com.ORCID http://orcid.org/0000-0002-3007-978X
University of Electronic Science and Technology of China · CN

Funding

Sichuan Province Science and Technology Support Program No. 18GJHZ0248 & 18ZDYF0569
6 · The paper itself

Abstract

Treatment of Parkinson's disease with levodopa/carbidopa/entacapone (LCE) has been studied for a long time. However, the efficacy and safety of LCE in the treatment of early Parkinson's disease (PD) still need to be assessed. Our objective was to do a meta-analysis of relevant randomized controlled trials (RCTs) to evaluate the efficacy and safety of LCE for early PD. PubMed, Embase, the Cochrane Library, and the Web of Science were searched for RCTs with "levodopa/carbidopa/entacapone" and "Parkinson's disease" as keywords. The search period was from inception to October 2018. The quality of included studies was strictly evaluated. We evaluated the quality of included studies strictly and six studies met all inclusion criteria. The results showed that LCE could improve activities of daily living and motor function in PD patients. However, LCE therapy was associated with higher risks of total AEs and single AEs compared with traditional therapy.

Indexed as

CarbidopaParkinson DiseaseAntiparkinson AgentsCatecholsDrug CombinationsHumansLevodopaNitrilesAntiparkinson AgentsCarbidopaCatecholsDrug CombinationsentacaponeLevodopaNitrilesAdverse eventsEarly Parkinson’s diseaseLevodopa/carbidopa/entacaponeTreatment of Parkinson’s disease

Identifiers

PMID32162166
OpenAlexW3012028090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.